The DOI matches its Crossref record.
The Global Portfolio of New Antimalarial Medicines Under Development
Open accessAbstract
With the elimination of malaria now considered a realistic goal, it would be useful for scientists and policy makers to have an inventory of the arsenal of antimalarials, current and prospective, that could help make this goal a reality. In order to provide an overview of antimalarial projects in recent clinical development, we review here the global portfolio of antimalarial drugs in clinical phases of development complemented by projects in the preclinical and early discovery phases. The portfolio is discussed in terms of the novelty of the new molecules and their potential health impact in terms of addressing the requirements for the control and eventual eradication of malaria.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Spiroindolones, a Potent Compound Class for the Treatment of Malaria
Rottmann, M., McNamara, C., Yeung, B. K. S., Lee, M. C. S., Zou, B., Russell, B., Seitz, P., Plouffe, D. M., Dharia, N. V., Tan, J., et al. (2010) · Science · doi:10.1126/science.1193225 · Cited by 1,206
Next‐generation antimalarial drugs: hybrid molecules as a new strategy in drug design
Muregi, F. W., & Ishih, A. (2010) · Drug Development Research · doi:10.1002/ddr.20345 · Cited by 310
Drug-Resistant Malaria: The Era of ACT
Lin, J. T., Juliano, J. J., & Wongsrichanalai, C. (2010) · Current Infectious Disease Reports · doi:10.1007/s11908-010-0099-y · Cited by 121
Metadata
- Authors
- Olliaro, P., & Wells, T.
- Venue
- Clinical Pharmacology & Therapeutics
- Publisher
- Wiley
- Published
- 2009-04-29
- Volume
- 85
- Issue
- 6
- Pages
- 584-595
- ISSN
- 0009-9236 (ISSN-L)
- 1532-6535
- OpenAlex
- W2171565780
- Cited by
- 168
- References
- 0
- FWCI
- 26.25
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The Global Portfolio of New Antimalarial Medicines Under Development. https://app.cochat.ai/papers/10.1038/clpt.2009.51
- The paper
- Olliaro, P., & Wells, T. (2009). The Global Portfolio of New Antimalarial Medicines Under Development. Clinical Pharmacology & Therapeutics. https://doi.org/10.1038/clpt.2009.51
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
